{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:11:30Z","timestamp":1790946690575,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Genzyme Gaucher generation program","award":["GZ-2011-10810"],"award-info":[{"award-number":["GZ-2011-10810"]}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ymgme.2018.06.007","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T10:27:55Z","timestamp":1528972075000},"page":"278-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Impact of sphingolipids on osteoblast and osteoclast activity in Gaucher disease"],"prefix":"10.1016","volume":"124","author":[{"given":"Matthew C.","family":"Reed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Capucine","family":"Schiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Heales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul B.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2018.06.007_bb0005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0006-291X(65)90743-6","article-title":"Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease","volume":"18","author":"Brady","year":"1965","journal-title":"Biochem Biophys Res Commun."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0010","first-page":"299","article-title":"Gaucher disease: clinical profile and therapeutic developments","volume":"4","author":"Cox","year":"2010","journal-title":"Biologics"},{"key":"10.1016\/j.ymgme.2018.06.007_bb0015","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry. Demographics and disease of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0020","first-page":"72","article-title":"Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history","volume":"1","author":"Baris","year":"2014","journal-title":"Pediatr Endocrinol Rev. Suppl"},{"issue":"S1","key":"10.1016\/j.ymgme.2018.06.007_bb0025","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1002\/ajh.24063","article-title":"Gaucher disease types 1 and 3: phenotypic characterization of large populations from the ICGG Gaucher registry","volume":"90","author":"Grabowski","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0030","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","article-title":"Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy","volume":"90","author":"Deegan","year":"2011","journal-title":"Medicine"},{"issue":"S1","key":"10.1016\/j.ymgme.2018.06.007_bb0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1259\/bjr.75.suppl_1.750013","article-title":"Imaging and quantifying skeletal involvement in Gaucher disease","volume":"75","author":"Maas","year":"2002","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.beem.2014.08.010","article-title":"The clinical spectrum and pathophysiology of skeletal complications in lysosomal storage disorders","volume":"29","author":"Clarke","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bcmd.2013.04.006","article-title":"Enhanced differentiation of osteoclasts from mononuclear precursors in patients with Gaucher disease","volume":"51","author":"Reed","year":"2013","journal-title":"Blood Cells, Mol Dis."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2015.05.009","article-title":"Proinflammatory and proosteoclastogenic potential of peripheral blood mononuclear cells from Gaucher patients: Implication for bone pathology","volume":"55","author":"Mucci","year":"2015","journal-title":"Blood Cells Mol Dis."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0055","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc Natl Acad Sci."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0060","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/hmg\/ddu538","article-title":"Glucocerebrosidase deficiency in zebrafish affects primary bone ossification through increased oxidative stress and reduced Wnt\/\u03b2-catenin signaling","volume":"24","author":"Zancan","year":"2015","journal-title":"Hum Mol Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2018.06.007_bb0065","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/ijms18010112","article-title":"Osteocyte alterations induce osteoclastogenesis in an in vitro model of Gaucher disease","volume":"18","author":"Bondar","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0070","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bcmd.2005.08.004","article-title":"Increased incidence of cancer in adult Gaucher disease in Western Europe","volume":"36","author":"de Fost","year":"2006","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0075","first-page":"4569","article-title":"Gaucher disease and cancer incidence: a study from the Gaucher Registry","volume":"105","author":"Rosenbloom","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ymgme.2018.06.007_bb0080","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/jbmr.2387","article-title":"Unveiling skeletal fragility in patients diagnosed with MGUS: No longer a condition of undetermined significance?","volume":"29","author":"Drake","year":"2014","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0085","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1002\/cncr.20652","article-title":"Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades","volume":"101","author":"Kyle","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ymgme.2018.06.007_bb0090","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00277-016-2657-3","article-title":"Clinical significance of osteoblast precursors and osteoclast precursors in earlier diagnosis and monitoring of myeloma bone disease","volume":"95","author":"Fu","year":"2016","journal-title":"Ann Hematol."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0095","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12253-008-9092-2","article-title":"Quantification of dendritic cells and osteoclasts in the bone marrow of patients with monoclonal gammopathy","volume":"15","author":"Josselin","year":"2009","journal-title":"Pathol Oncol Res."},{"issue":"6","key":"10.1016\/j.ymgme.2018.06.007_bb0100","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1158\/0008-5472.CAN-03-1131","article-title":"Cancer and the microenvironment: myeloma-osteoclast interactions as a model","volume":"64","author":"Yaccoby","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0105","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF02591662","article-title":"The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma","volume":"21","author":"Bataille","year":"1992","journal-title":"Int J Clin Lab Res."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0110","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/sj.leu.2404228","article-title":"BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma","volume":"20","author":"Abe","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ymgme.2018.06.007_bb0115","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.2013.090977","article-title":"Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells","volume":"99","author":"Noll","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ymgme.2018.06.007_bb0120","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.bbalip.2011.06.009","article-title":"Lipid classification, structures and tools","volume":"1811","author":"Fahy","year":"2011","journal-title":"Biochim Biophys Acta - Mol Cell Biol Lipids"},{"key":"10.1016\/j.ymgme.2018.06.007_bb0125","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.chroma.2015.01.004","article-title":"Lipidomic profiling of plasma and urine from patients with Gaucher disease during enzyme replacement therapy by nanoflow liquid chromatography\u2013tandem mass spectrometry","volume":"1381","author":"Byeon","year":"2015","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ymgme.2018.06.007_bb0130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2018.06.007_bb0135","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bcmd.2015.01.006","article-title":"Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard","volume":"54","author":"Mirzaian","year":"2015","journal-title":"Blood Cells Mol Dis."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0140","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4161\/cbt.11.2.14624","article-title":"Dysregulation of sphingolipid metabolism in cancer","volume":"11","author":"Ryland","year":"2011","journal-title":"Cancer Biol Ther."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrm2329","article-title":"Principles of bioactive lipid signalling: lessons from sphingolipids","volume":"9","author":"Hannun","year":"2008","journal-title":"Nat Rev Mol Cell Biol."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0150","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2174\/187152011797655177","article-title":"Ceramide-based therapeutics for the treatment of cancer","volume":"11","author":"Barth","year":"2011","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0155","doi-asserted-by":"crossref","first-page":"12979","DOI":"10.1074\/jbc.M809500200","article-title":"Acid \u03b2-glucosidase 1 counteracts p38\u03b4-dependent induction of interleukin-6: Possible role for ceramide as an anti-inflammatory lipid","volume":"284","author":"Kitatani","year":"2009","journal-title":"J Biol Chem."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0160","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","article-title":"Osteopenia in Gaucher disease develops early in life: Response to imiglucerase enzyme therapy in children, adolescents and adults","volume":"46","author":"Mistry","year":"2011","journal-title":"Blood Cells, Mol Dis."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0165","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1084\/jem.20060921","article-title":"Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases","volume":"203","author":"Gadola","year":"2006","journal-title":"J Exp Med."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0170","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1172\/JCI117997","article-title":"Glucosylceramides stimulate murine epidermal hyperproliferation","volume":"95","author":"Marsh","year":"1995","journal-title":"J Clin Invest."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0175","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0014-5793(98)00005-2","article-title":"Sphingomyelinase and ceramide inhibit formation of F-actin ring in and bone resorption by rabbit mature osteoclasts","volume":"422","author":"Takeda","year":"1998","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0180","doi-asserted-by":"crossref","first-page":"46031","DOI":"10.1074\/jbc.M104464200","article-title":"Lactosylceramide is essential for the osteoclastogenesis mediated by macrophage-colony-stimulating factor and receptor activator of nuclear factor-\u03baB ligand","volume":"276","author":"Iwamoto","year":"2001","journal-title":"J Biol Chem."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0185","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1084\/jem.20101474","article-title":"Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo","volume":"207","author":"Ishii","year":"2010","journal-title":"J Exp Med."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0190","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.1074\/jbc.M112.413583","article-title":"Sphingosine 1-phosphate (S1P) receptors 1 and 2 coordinately induce mesenchymal cell migration through S1P activation of complementary kinase pathways","volume":"288","author":"Quint","year":"2013","journal-title":"J Biol Chem."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0195","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ab.2004.02.002","article-title":"An alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction","volume":"329","author":"Gregory","year":"2004","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0200","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/bonekey.2013.215","article-title":"Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit","volume":"3","author":"Sims","year":"2014","journal-title":"Bonekey Rep."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0205","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.gene.2013.09.072","article-title":"Uncoupling of osteoblast-osteoclast regulation in a chemical murine model of gaucher disease","volume":"532","author":"Mucci","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.ymgme.2018.06.007_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069293","article-title":"A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patients","volume":"8","author":"Lecourt","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.06.007_bb0215","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/scd.2011.0365","article-title":"Bone marrow microenvironment in an in vitro model of Gaucher disease: Consequences of glucocerebrosidase deficiency","volume":"21","author":"Lecourt","year":"2012","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0220","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cca.2015.07.026","article-title":"Rapid, single-phase extraction of glucosylsphingosine from plasma: a universal screening and monitoring tool","volume":"450","author":"Fuller","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2018.06.007_bb0225","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","article-title":"Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study","volume":"73","author":"Sims","year":"2008","journal-title":"Clin Genet."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0230","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00223-008-9143-4","article-title":"Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat","volume":"83","author":"Mikosch","year":"2008","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0235","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature07713","article-title":"Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis","volume":"458","author":"Ishii","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2018.06.007_bb0240","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nrc1411","article-title":"Biologically active sphingolipids in cancer pathogenesis and treatment","volume":"4","author":"Ogretmen","year":"2004","journal-title":"Nat Rev Cancer."},{"key":"10.1016\/j.ymgme.2018.06.007_bb0245","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.bbalip.2013.11.004","article-title":"Gaucher disease and Fabry disease: New markers and insights in pathophysiology for two distinct glycosphingolipidoses","volume":"1841","author":"Ferraz","year":"2014","journal-title":"Biochim Biophys Acta - Mol Cell Biol Lipids"},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2018.06.007_bb0250","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bbalip.2007.11.004","article-title":"Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic intervention","volume":"1781","author":"Groener","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2018.06.007_bb0255","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.chroma.2017.10.038","article-title":"Optimization of ultra-high pressure liquid chromatography - tandem mass spectrometry determination in plasma and red blood cells of four sphingolipids and their evaluation as biomarker candidates of Gaucher's disease","volume":"24","author":"Chipeaux","year":"2017","journal-title":"J Chromatogr A."},{"issue":"1","key":"10.1016\/j.ymgme.2018.06.007_bb0260","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00428-005-1246-y","article-title":"Lactosylceramide in lysosomal storage disorders: a comparative immunohistochemical and biochemical study","volume":"447","author":"H\u016flkov\u00e1","year":"2005","journal-title":"Virchows Arch."},{"issue":"1","key":"10.1016\/j.ymgme.2018.06.007_bb0265","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1006\/mgme.2001.3269","article-title":"Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: implications for the prediction of disease severity","volume":"75","author":"Whitfield","year":"2002","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218302130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218302130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T11:22:32Z","timestamp":1532949752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218302130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1096719218302130"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.06.007","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of sphingolipids on osteoblast and osteoclast activity in Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}